Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Comment: The success of immunotherapy means we have to change our mindset as we treat patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.19
Views: 392
Rating:

Dr David Graham and Dr Edward B. Garon

Dr David Graham and Dr Edward B. Garon comment on data, during a press conference at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, from the KEYNOTE-001 trial.

This was a phase Ib randomised trial studying the use of pembrolizumab in aNSCLC patients who had not been previously treated and also those who had received prior treatment.

Watch Dr Garon's interview here, and press conference here.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation